The roles of complement factor C5a and CINC-1 in glucose transport, ultrafiltration, and neutrophil recruitment during peritoneal dialysis

Peritoneal Dialysis International

Volumn 26, Issue 6, 2006, Pages 688-696

  Bazargani, Farhan ^a   Rother, Russell P ^b   Braide, Magnus ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ALEXION PHARMACEUTICALS   (United States)

Author keywords

CINC 1; Complement factor C5a; Neutrophil recruitment; Ultrafiltration

Indexed keywords

COMPLEMENT COMPONENT C5A; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT 1; GLUCOSE; HISTAMINE; INTERLEUKIN 8; MONOCLONAL ANTIBODY; PERITONEAL DIALYSIS FLUID; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; CHEMOTAXIS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; IN VIVO STUDY; INDWELLING CATHETER; LEUKOCYTE AGGREGATION; MALE; METABOLIC ACTIVATION; NEUTROPHIL; NEUTROPHIL COUNT; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; ULTRAFILTRATION;

EID: 33846685551     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080602600614     Document Type: Article

References (44)

1. Flanigan MJ, Freeman RM, Lim VS. Cellular response to peritonitis among peritoneal dialysis patients. Am J Kidney Dis 1985; 6:420-4.
2. Zemel D, Imholz AL, de Waart DR, Dinkla C, Struijk DG, Krediet RT. Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994; 46:1422-30.
3. Lin CY, Lin CC, Huang TP. Serial changes of interleukin-6 and interleukin-8 levels in drain dialysate of uremic patients with continuous ambulatory petitoneal dialysis during peritonitis. Nephron 1993; 63:404-8.
4. Reddingius RE, Schröder CH, Daha MR, Willems HL, Koster AM, Monnens LA. Complement in serum and dialysate in children on continuous ambulatory peritoneal dialysis. Perit Dial Int 1995; 15:49-53.
5. Young GA, Kendall S, Browrjohn AM. Complement activation during CAPD. Nephrol Dial Transplant 1993; 8:1372-5.
6. Homma S, Masunaga Y, Kurosu M, Inoue M, Sakurai T, Asano Y. Changes in peritoneal coagulation and fibrinolysis after discontinuation of chronic peritoneal dialysis. Perit Dial Int 2002; 22:178-83.
7. Honda K, Nitta K, Horita S, Yamura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72: 171-6.
8. Dobbie JW. Peritoneal ultrastructure and changes with continuous ambulatory peritoneat dialysis. Perit Dial Int 1993; 13(Suppl 2):S585-7.
9. Wilson JH, Bonta IL. Human peritoneal macrophages: clinical models of inflammation and potential targets of antiinflammatory drugs. Agents Actions 1986; 17(3-4): 338-41.
10. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66:1257-65.
11. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-38.
12. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
13. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: The effect of a new biocompatibte peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
14. Sjoland JA, Smith Pedersen R, Jespersen J, Gram J. Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. Nephrol Dial Transplant 2004; 19:1264-8.
15. Sinitsyn W, Bokchubaev ET, Mamontova AG, Ovtrakht NV, Nasonov EL, Konovalov GA, et al. C3a and C5a anaphylatoxins bind to heparin-based sorbent in low density lipoprotein apheresis: in vitro and in vivo investigations. Artif Organs 1992; 16:291-3.
16. Huey R, Fukuoka Y, Hoeprich PD Jr, Hugli TE. Cellular receptors to the anaphylatoxins C3a and C5a. Biochem Soc Symp 1986; 51:69-81.
17. Matzner Y, Marx G, Drexler R, Eldor A. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 1984; 52:134-7.
18. Bazargani F, Albrektsson A, Yahyapour N, Braide M. Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation. Perit Dial Int 2005; 25:394-404.
19. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, et al. Predominant role for C5b-9 in renalischemia/reperfusion injury. J Clin Invest 2000; 105:1363-71.
20. Tofukuji M, Stahl GL, Metais C, Tomita M, Agah A, Bianchi C, et al. Mesenteric dysfunction after cardiopulmonary bypass: role of complement C5a. Ann Thorac Surg 2000; 69:799-807.
21. Mulligan MS, Schmid E, Beck-Schimmer B, Till GO, Friedl HP, Brauer RB, et al. Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest 1996; 98: 503-12.
22. Matis LA, Rollins SA. Complement-specific antibodies: designing novel anti-inflammatories. Nat Med 1995; 1:839-42.
23. Laudes IJ, Chu JC, Sikranth S, Huber-Lang M, Guo RF, Riedemann N, et al. Anti-c5a ameliorates coagulation/fibrinolytic protein changesin a rat model of sepsis. Am J Pathol 2002; 160:1867-75.
24. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 1995; 268(1 Pt 2):H448-H457.
25. Foreman KE, Glovsky MM, Warner RL, Horvath SJ, Ward PA. Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells. Inflammation 1996; 20:1-9.
26. Tonnesen MG, Anderson DC, Springer TA, Knedler A, Avdi N, Henson PM. Adherence of neutrophils to cultured human microvascular endothelial cells. Stimulation by chemotactic peptides and Lipid mediators and dependence upon the Mac-1, LFA-1, p150,95 glycoprotein family. J Clin Invest 1989; 83:637-46.
27. Collins PD, Jose PJ, Williams TJ. The sequential generation of neutrophil chemoattractant proteins in acute inflammation in the rabbitin vivo. Relationship between C5a and proteins with the characteristics of IL-8/neutrophil-activating protein 1. J Immunol 1991; 146:677-84.
28. Deas DE, Mackey SA, McDonnell HT. Systemic disease and periodontitis: manifestations of neutrophil dysfunction. Periodontol 2000 2003; 32:82-104.
29. Ramos CD, Heluy-Neto NE, Ribeiro RA, Ferreira SH, Cunha FQ. Neutrophil migration induced by IL-8-activated mast cells is mediated by CINC-1. Cytokine 2003; 21:214-23.
30. Shibata F, Konishi K, Nakagawa H. Identification of a common receptor forth three types of rat cytokine-induced neutrophil chemoattractants (CINCs). Cytokine 2000; 12: 1368-73.
31. Fredholm B, Haegermark O. Histamine release from rat mast cells induced by a mast cell degranulating fraction in bee venom. Acta Physiol Scand 1967; 69:304-12.
32. Nannmark U, Braide M, Bagge U. Leukocyte deformability - a comparison between different methods for separation of rat leukocytes from whole blood. Int J Microcirc Clin Exp 1989; 8:177-82.
33. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77:394-8.
34. Sims PJ, Wiedmer T. Induction of cellular procoagutant activity by the membrane attack complex of complement. Semin Cell Biol 1995; 6:275-82.
35. Alonso A, Bayon Y, Crespo MS. The expression of cytokine-induced neutrophil chemoattractants (CINC-1 and CINC-2) in rat peritoneal macrophages is triggered by Fc gamma receptor activation: study of the signaling mechanism. Eur J Immunol 1996; 26:2165-71.
36. Johnson AR, Hugli TE, Muller-Eberhard HJ. Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology 1975; 28:1067.
37. Kubes P. Ruthenium red as measure of mast cell activation. Methods Enzymol 1999; 301:22-7.
38. Hartmann K, Henz BM, Kruger-Krasagakes S, Kohl J, Burger R, Guhl S, et al. C3a and C5a stimulate chemotaxis of human mast cells. Blood 1997; 89:2863-70.
39. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77:1033-79.
40. Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. FASEB J 1997; 11:51-9.
41. Norrby K, Ostergaard P. A 5.0-kD heparin fraction systemically suppresses VEGF165-mediated angiogenesis. Int J Microcirc Clin Exp 1997; 17:314-21.
42. Luo HY, Wead WB, Yang S, Wilson MA, Harris PD. Nitric oxide mediates C5a-induced vasodilation in the small intestine. Microcirculation 1995; 2:53-61.
43. Breborowicz A, Wieczorowska-Tobis K, Korybalska K, Potubinska A, Radkowski M, Oreopoulos DG. The effect of a nitric oxide inhibitor (L-NAME) on peritoneal transport during dialysis in rats. Perit Dial Int 1998; 18:188-92.
44. Rosengren BI, Rippe B. Blood flow limitation in vivo of small solute transfer during peritoneal dialysis in rats. J Am Soc Nephrol 2003; 14:1599-604.